52 filings
8-K
FHTX
Foghorn Therapeutics Inc
16 Apr 24
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
7:01am
8-K
FHTX
Foghorn Therapeutics Inc
9 Apr 24
Regulation FD Disclosure
4:41pm
8-K
FHTX
Foghorn Therapeutics Inc
7 Mar 24
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
7:11am
8-K
FHTX
Foghorn Therapeutics Inc
8 Feb 24
Regulation FD Disclosure
7:04am
8-K
FHTX
Foghorn Therapeutics Inc
17 Jan 24
Departure of Directors or Certain Officers
4:09pm
8-K
qbm gb6csb
8 Jan 24
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
7:04am
8-K
zh92fveytz3h8k1j
3 Jan 24
Foghorn Therapeutics Announces CFO Departure
4:18pm
8-K
vfke2c1k
2 Nov 23
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
7:03am
8-K
hexb3 16s4jf3orcfr
8 Sep 23
Regulation FD Disclosure
7:04am
8-K
kyvy60cy cqkc
31 Aug 23
Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
7:04am
8-K
fzssfwv
10 Aug 23
Termination of a Material Definitive Agreement
4:08pm
8-K
wpee5nv
8 Aug 23
Foghorn Therapeutics Announces Chief Medical Officer Succession
7:05am
8-K
1dyyx2a1caik2rulg
4 Aug 23
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
7:05am
8-K
1gvwdeoertfuav9f0
28 Jun 23
Regulation FD Disclosure
7:05am
8-K
3ul9 4mrta4ij
22 Jun 23
Submission of Matters to a Vote of Security Holders
4:13pm
8-K
915hxesioibl6uxenb
5 Jun 23
Regulation FD Disclosure
7:02am
8-K
0dj7o
8 May 23
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
7:03am
8-K
oo3jw5bg3q7zbi
24 Apr 23
Foghorn Therapeutics Provides an Update on FHD-609
7:05am
8-K
lw1y30jxnh yjsx5g0t
9 Mar 23
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
7:12am
8-K
y4162fso
8 Mar 23
Regulation FD Disclosure
7:10am